Cannabis legalization is a movement and a reality that is happening right now in the United States, where institutional investors have kept a close watch and are ready to pounce.
I’m ready too, with an expert team of researchers and stock watchers so that I can bring you the next multi-bagger to boost your bottom line. Wealth Research Group is all about buying great companies at the bottom and letting the market catch up to the company’s real value.
I remember back in July 2001, when the MMAR (Marijuana Medical Access Regulations) was enacted, paving the way for the legalization of marijuana for medicinal use. It was a milestone which I knew would lead to bigger and better things for smart investors, but there just wasn’t an easy way to capitalize on it at the time.
Now, with easy online access to brokers and a plethora of cannabis stocks to choose from, there’s absolutely no excuse to hesitate if you’re looking to profit from the cannabis revolution that’s taking place right now.
When you’ve been in this business for as long as I have, you start to see patterns, and what I’m seeing is a global cannabis market that’s gearing up for a big move. And let me tell you, when marijuana stocks move, they really move. They might take a breather for a while, and then all of a sudden, the stock price jumps up and catches most retail investors off guard.
Just think of how much money was made when the U.S. marijuana index shot to the moon in late 2016 and late 2018:
Courtesy of MarijuanaIndex.com
These jumps will happen again and again for investors who position themselves correctly, at the right time and with the right company. Like other commodities, investing in cannabis is a matter of timing and according to my research, there’s never been a better time than now to get in.
The demand for cannabis for medical use is as high as it has ever been, and other states and nations are looking to places like California to lead the way.
Just how big is this cannabis market? Chances are, it’s bigger than you think, even to the point of dwarfing the vast majority of other major commodity markets:
Courtesy of Statista, The World Gold Council, The Silver Institute, The United Nations
With such a massive market and a deep well of profits to draw from, I’ve tasked my research team with identifying the absolute best way to position oneself in the current market environment.
What we found is none other than Fincanna Capital Corp. (CSE:CALI, OTC:FNNZF), a royalty company focused on the licensed U.S. medical cannabis industry. Fincanna’s mission is to combine extensive investment expertise and industry experience in funding best-in-class businesses in the American licensed medical cannabis industry, with a focus on California.
Why California? Simple: California is the largest cannabis market in North America, having representing a big piece of the pie in legal cannabis sales:
Courtesy of Fincanna Investor Presentation
Fincanna is strategically positioned right at the crux of the action in California. The firm provides funding to Cultivation Technologies Inc. for its planned, fully-entitled, large-scale indoor medical cannabis facility to be developed in Coachella, Southern California.
This stake in Cultivation Technologies Inc. is ideal because they have demonstrated the ability to navigate permitting in California – the largest medical cannabis market in North America.
Along with its other advantages, strategic partnerships are bound to give Fincanna the edge over any competitor in the California cannabis market. For instance, FinCanna will receive a perpetual royalty equal to 10% of gross revenues of Green Compliance, with its state-of-the-art enterprise compliance and point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators.
Furthermore, Fincanna will receive a tiered corporate royalty ranging from 7.5% to 14% of Gram Co Holdings’ revenues; Gram Co has leased a facility in Oakland, California in which they are retrofitting a large, state-of-the-art medical cannabis extraction laboratory expected to be operating by the end of 2018.
President and CEO Andriyko Herchak is bringing Fincanna, along with his 20 years of executive leadership experience with publicly traded companies, to the forefront of the California medical cannabis market.
And now there’s breaking news: has executed an Expanded Royalty Agreement with Refined Resin Technologies Inc. Based in Oakland, California, Refined Resin Technologies is a cannabinoid research and refinery company that provides B2B and B2C products and services to licensed dispensaries and distributors in the medical cannabis supply chain. As a result, FinCanna will receive a tiered corporate royalty ranging from 5% to 14% of Refined Resin Technologies’ annual revenues.
With so many revenue streams and a series of highly profitable joint ventures, Fincanna has left absolutely no room for the competition in California’s robust medical cannabis market – and as an investor, I wouldn’t want it any other way. Consider Fincanna as your best move right now for tremendous returns in the explosive cannabis industry.
Best Regards,
Lior Gantz
President, WealthResearchGroup.com
Legal Notice: Never base any decision off of our advertorials. Wealth Research Group stock profiles are intended to be stock ideas, NOT recommendations. The ideas we present are high risk and you can lose your entire investment, we are not stock pickers, market timers, investment advisers, and you should not base any investment decision off our website, emails, videos, or anything we publish. Please do your own research before investing. It is crucial that you at least look at current public filings and read the latest press releases. Information contained in this profile was extracted from current documents filed with the public, the company web site and other publicly available sources deemed reliable. Never base any investment decision from information contained in our website or emails or any or our publications. Our report is not intended to be, nor should it be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell securities, or as a recommendation to purchase anything. This publication may provide the addresses or contain hyperlinks to websites; we disclaim any responsibility for the content of any such other websites. We are long FinCanna Capital Corp. and own shares of the company that we will not sell during our active marketing coverage. The company has paid two hundred and fifty thousand Canadian dollars for one year of digital advertising, which includes emails, videos, and interviews. Please use our site as a place to get ideas. Enjoy our videos and news analysis, but never make an investment decision off of anything we say.
Please read our full disclaimer at WealthResearchGroup.com/disclaimer